The Global Sustained Release Excipients Market size was valued at USD 1.26 Billion in 2022 and is expected to surpass USD 2.60 Billion by 2031, expanding at a CAGR of 8.4% during the forecast period, 2023 – 2031. The growth of the market is attributed to the rising requirement of pediatric and geriatric dosage forms and increasing number of patent expirations.
Oral sustained drug release systems are inimitable in the formulation and accurately developed for management and treatment of several disorders. As these drugs are ease to manage, they need fewer doses and each day one dose is sufficient, this make simpler treatment of chronic diseases. All these factors are key factors responsible for endorsing the adoption of these technologies. Launch of sustained release drug delivery systems are encouraging patient-centric therapy also gives higher efficiency of drugs.
Increasing awareness about added benefits of sustained release formulations among people aids the market expansion in coming years. This sustained release formulations considerably decreases frequency of dosage and improve patient compliance. Meticulous designing and development is required for effective and easy to manage the sustained release systems. At the time of designing a specific drug delivery system several parameters including type of drug release mechanism, biocompatibility, and dose titration & formulation are considered. In the development of sustained drug release systems, groundbreaking research and innovation is needed. But they are costly as compare to conventional pharmaceutical formulations.
Sustained drug release systems allow personalized medications of active ingredient over longer period of time up to 24 hours. Generally this is achievable with the usage of film coating, sustained-release drug-loaded granules, and sustained release matrix. This sustained release formulations is gained substantial power in the pharmaceutical industry. It is major tool for improvement in patient’s experience of existing and new drugs.
Market Trends, Drivers, Restraints, and Opportunities
-
Prevalence of chronic and acute diseases is major factor responsible for propelling the expansion of the market in the coming years.
-
Increased benefits of conventional form of dosage and antibiotic resistance are anticipated to drive the market growth.
-
Rising government initiatives and increasing prevention and early intervention strategies are expected to fuel the growth of the market.
-
Increasing number of patent lapses and removing needs of pediatric and geriatric measurements structures are anticipated to boost the market expansion over the forecast period.
-
Stringent government regulations and high cost of drugs are major factors responsible for hampering the market growth over the forecast period.
-
Dose dumping is projected to impede the market expansion in the coming years.
Scope of Sustained Release Excipients Market Report
The report on the global sustained release excipients market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes
|
Details
|
|
Report Title
|
Sustained Release Excipients Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
|
Base Year
|
2022
|
|
Historic Data
|
2016–2021
|
|
Forecast Period
|
2023–2031
|
|
Segmentation
|
Products (Polymers, Gelatin, Minerals, Sugars, Alcohol, and Chitosan), Routes of Administration (Oral, Transdermal, Ophthalmic, Intravenous, and Others), Technologies (Targeted Delivery, Micro Encapsulation, Wurster Technique, Transdermal, Implants, Coacervation, and Others)
|
|
Regional Scope
|
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
|
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
|
|
Key Players Covered in the Report
|
Depomed, Inc.; Coating Place, Inc.; Corium International, Inc.; Orbis Biosciences, Inc.; Capsugel; Aradigm Corporation; and Alkermes plc.
|
Sustained Release Excipients Market Segment Insights
Polymers segment is projected to hold a key market share
On the basis of products, the sustained release excipients market is divided into polymers, gelatin, minerals, sugars, alcohol, and chitosan. The polymers segment is expected to hold a key share of the market during the forecast period owing to their high usage in sustained release formulations. Larger contribution of sugars are attributed to properties including porous nature and spherical shape. It advances flowability and lowers friability.
However, the minerals segment is anticipated to expand at a rapid pace during the forecast period due to its properties such as high absorption capacity, swelling capacity, reactivity to acids, and specific surface area. Titanium oxide’s use in Amrix, Kadian, OxyContin, and Conzip as a major filling agent indicates the rise in use of minerals in different formulations, which is anticipated to drive the segment growth.
Intravenous segment is expected to expand at a rapid pace
In terms of routes of administration, the market is segregated into oral, transdermal, ophthalmic, intravenous, and others. The oral segment is expected to account for a key share of the market in the coming years owing to premeasured doses and noninvasive nature of the route. Moreover, convenient with respect to storage and portability are projected to drive the segment growth over the forecast period.
On the other hand, the intravenous segment is anticipated to expand at a rapid pace during the forecast period owing to ease of application, cost effective, reduced dosage frequency, and minimum adverse effects. Furthermore, long-acting injectable formulations, better patient compliance, and assessed drug-release profile throughout a definite period of time are projected to boost the expansion of the market in the coming years.
The transdermal segment is also projected to expand at a robust pace during the forecast period. Ophthalmic segment is anticipated to register a rapid CAGR in the coming years as increasing number of launch of products which aids to treatment of diabetic macular edema, cytomegalovirus, and chronic non-infectious posterior uveitis. The others segment includes subcutaneous, vaginal, and intramuscular.
Transdermal segment is anticipated to register a substantial CAGR
Based on technologies, the sustained release excipients market is segmented into targeted delivery, micro encapsulation, wurster technique, transdermal, implants, coacervation, and others. The targeted delivery segment is expected to account for a key share of the market in the coming years due to huge number of companies have strong product portfolio. Targeted delivery includes the drug delivery to a preferred site of action and prevention of drugs from reaching unintended parts of the body which prevents the chances of drug toxicity. Pfizer’s drug is Lyrica (pregabalin) which is used for postherpetic neuralgia, diabetic, and peripheral neuropathic pain.
However, the transdermal segment is anticipated to expand at a rapid pace during the forecast period owing to increasing use in the treatment of chronic diseases. Corium International, Inc. developed Corplex technology which injects small-molecule drugs in the skin, which is the simplest method of drug delivery. The micro encapsulation segment is growing with rising number of market players who are adopting this method. As compare to conventional drug delivery systems it results lower toxicity. Hence, this technology is preferred for geriatric and pediatric patients.
North America is anticipated to dominate the market
On the basis of regions, the sustained release excipients market is categorized as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market of North America is anticipated to expand at an impressive CAGR during the forecast period. The regional market growth can be attributed to availability of highly sophisticated technologies and increasing investment in research and development. Moreover, presence of leading pharmaceutical and biopharmaceutical market players and well-developed research infrastructure are expected to drive the regional market growth. Also, increasing focus on drug discovery and adoption of advanced technologies are driving the market growth of the region.
On the other hand, the market of Asia Pacific is expected to exhibit a rapid growth rate in the coming years owing to increasing demand of highly effective therapeutics, developing healthcare infrastructure, and rising prevalence of chronic diseases.
Segments
The global sustained release excipients market has been segmented on the basis of
Products
- Polymers
- Gelatin
- Minerals
- Sugars
- Alcohol
- Chitosan
Routes of administration
- Oral
- Transdermal
- Ophthalmic
- Intravenous
- Others
Technologies
- Targeted Delivery
- Micro Encapsulation
- Wurster Technique
- Transdermal
- Implants
- Coacervation
- Others
Regions
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
Competitive Landscape
Key players competing in the sustained release excipients market are Depomed, Inc.; Coating Place, Inc.; Corium International, Inc.; Orbis Biosciences, Inc.; Capsugel; Aradigm Corporation; and Alkermes plc.
Major market players are implementing several market strategies such as mergers, acquisitions, partnerships, collaborations, capacity expansion, and product launches to enhance their market shares. For instance, in January 2016, Capsugel acquired Xcelience and Powdersize which helped in expansion of its dosage.
Request For Customization
Enquiry Before Buying
Speak With Analyst
